Disclosed embodiments include devices and methods for shaping, bending, and/or volumetrically reducing rigid cartilaginous structures, such as hyaline cartilage in the septum. In the case of septal cartilage, shaping, bending, or reducing the cartilage would be useful for reducing nasal obstruction or to improve the cosmetic appearance of the nose.

The present invention discloses hydrophobin mimics of formula (I) comprising a protein head group, hydrophilic linker and hydrophobic tail and to a process for synthesis of library of hydrophobin mimics thereof. The hydrophobin mimics of the present invention self-assemble to form protein nanoparticles/nanocontainer either alone or in a specified chemical environment. The hydrophobin mimics (I) of the present invention find application in area of bio-nanotechnology.

The present disclosure pertains compositions comprising anti-VEGF proteins and methods for producing such compositions.

The present invention relates to trypsin variants with improved enzymatic properties, and particularly relates to a mutated trypsin comprising an amino acid substitution at least at two amino acid positions leading to an increased affinity for the nucleophilic substrate and/or at least at two amino acid positions leading to a reduced hydrolysis activity.

Compositions and methods for therapeutic delivery are disclosed. More particularly, the present disclosure relates to nanoparticle compositions that sequester the activity of a target molecule while leaving other domains accessible to bind targeted tissues of interest. Methods for thrombus dissolution include administering a nanoparticle reversibly coupled to a target molecule that can dissolve a blood clot. Compositions and methods for inducing blood clotting are also disclosed. Methods for inducing blood clotting include administering a nanoparticle reversibly coupled to a target molecule that can induce the formation of a blood clot. Methods for sequestering a target molecule are also disclosed. The method includes reversibly coupling a target molecule to a nanoparticle having an affinity ligand that reversibly couples the target molecule, and thus, sequesters the target molecule activity until the target molecule interacts with its substrate resulting in the release of the target molecule.

The present disclosure pertains to compositions comprising aflibercept and methods for producing such compositions in chemically defined media and using chromatography to reduce amounts of certain aflibercept variants.

The invention concerns a process for the preparation of fish proteases from fish viscera, preferably from cod (Gadus genus) viscera. The fish proteases produced according to the invention have high specific enzymatic activity and are useful for food uses, for biomedical applications, in histology and tissue culture.

The present disclosure pertains to compositions comprising anti-VEGF proteins and methods for producing such compositions.

Current methods for detection of microbial contaminants on surfaces use swabbing/wiping to extract microbes for analysis. This removes easily transferable microbes but fails to extract microbes living in biofilms, which reduces sensitivity and may mask the true degree of contamination. The current disclosure provides an enzyme cocktail that disrupts the biofilm and improves the extraction of live microbes for analysis. Applicant's enzyme system is particularly useful for the application to a variety of surfaces, but particularly on a variety of food processing surfaces. Utilization of Applicant's enzyme cocktail makes possible the extraction of a representative sample of live microorganisms present on a surface, including film forming microorganisms, without affecting non-film forming microorganisms also present on a surface.

The present invention relates to polypeptide variants of porcine trypsin, to nucleic acid molecules encoding these variants, and to host cells comprising such nucleic acid molecules. It also relates to the use of these variants in methods for producing insulin. The invention further relates to the use of these variants as medicaments, as food ingredients, or as feed ingredients and to the use of these variants within a process of manufacturing a food ingredient or a feed ingredient.